Drug Profile
AVR 01
Alternative Names: AVR-01Latest Information Update: 25 Aug 2023
Price :
$50
*
At a glance
- Originator AVROBIO
- Class Gene therapies
- Mechanism of Action Gene modulators; Immunogenetic stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Acute myeloid leukaemia
Most Recent Events
- 12 Jul 2023 Suspended - Phase-I for Acute myeloid leukaemia in USA (IV) as AVROBIO is exploring strategic alternatives
- 28 Oct 2019 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia in USA (IV, Infusion)
- 02 Aug 2016 Phase-I clinical trials in Acute myeloid leukaemia in USA (IV)